<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01085344</url>
  </required_header>
  <id_info>
    <org_study_id>0019970022</org_study_id>
    <nct_id>NCT01085344</nct_id>
  </id_info>
  <brief_title>Canadian Hemophilia Prophylaxis Study</brief_title>
  <acronym>CHPS</acronym>
  <official_title>Moderate Term Musculoskeletal Outcomes With Escalating Dose Prophylaxis: the Canadian Hemophilia Prophylaxis Study Follow-up Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Hospital for Sick Children</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary prophylaxis given less frequently initially, with the infusion frequency increased if
      needed (Escalating Dose Prophylaxis), is likely to be less expensive and associated with
      fewer complications than standard prophylaxis while reducing disability to a greater degree
      than intermittent therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are 2 specific study objectives. The first is to estimate the incidence of target joint
      bleeding in patients with severe hemophilia A treated (for primary prophylaxis) with
      Escalating Dose Prophylactic factor replacement. The second objective is to obtain accurate
      estimates of the direct and indirect costs associated with this protocol for use in a
      cost-effectiveness model (comparing Escalating Dose with standard prophylaxis and with
      intermittent therapy).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1997</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the frequency of development of target joint bleeding</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>#of bleeding episodes</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>#of factor infusions</measure>
    <time_frame>6 months</time_frame>
    <description>number of infusions and reason for infusion to access cost of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>circulating inhibitor</measure>
    <time_frame>6 months</time_frame>
    <description>check for presence of inhitibors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>physical disability as measured by the CHAQ</measure>
    <time_frame>6 nibths</time_frame>
    <description>complete the Child Health Assessment Questionaire at each 6 month visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>joint damage as determined by the physiotherapy score</measure>
    <time_frame>6 months</time_frame>
    <description>Complete the modified Colarado Physiotherapy Assessment at each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complications arising from indwelling venous catheter</measure>
    <time_frame>6 months</time_frame>
    <description>collect information on any complications relating to indwelling venous catheters that some subject use.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Severe Hemophilia A</condition>
  <arm_group>
    <arm_group_label>Factor VIII</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>escalating dose Factor VIII</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS)</intervention_name>
    <description>escalating dose prophylaxis</description>
    <arm_group_label>Factor VIII</arm_group_label>
    <other_name>Recombinant Factor VIII (antihemophilic agent)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS)</intervention_name>
    <description>escalating dose</description>
    <arm_group_label>Factor VIII</arm_group_label>
    <other_name>recombinant factor VIII (antihemophilic agent)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe hemophilia A (factor level less than 2%).

          -  Age greater than 1 year and less than or equal to 2.5 years.

          -  Normal joints using the World Federation of Hemophilia orthopedic scale.

          -  Normal radiographs of joints in which bleeding has occurred using the World Federation
             of Hemophilia radiographic scale.

          -  Platelet count of &gt; 150,000.

          -  Informed consent to participate.

        Exclusion Criteria:

          -  Three or more clinically determined bleeds into any single elbow, knee or ankle.

          -  Presence or past history of a circulating inhibitor (level â‰¥ 0.5 Bethesda Units).

          -  Family judged to be non-compliant by the local hemophilia clinic director.

          -  Competing risk (symptomatic HIV infection, juvenile rheumatoid arthritis, metabolic
             bone disease, or other diseases known to cause or mimic arthritis.)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>30 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian M Feldman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2010</study_first_submitted>
  <study_first_submitted_qc>March 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2010</study_first_posted>
  <last_update_submitted>June 4, 2015</last_update_submitted>
  <last_update_submitted_qc>June 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Hospital for Sick Children</investigator_affiliation>
    <investigator_full_name>Brian Feldman</investigator_full_name>
    <investigator_title>Division Head, Rheumatology</investigator_title>
  </responsible_party>
  <keyword>hemophilia, prophylaxis, cost effectiveness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>May 10, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

